DrugPatentWatch Database Preview
ARNUITY ELLIPTA Drug Profile
When do Arnuity Ellipta patents expire, and what generic alternatives are available?
Arnuity Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. There are eight patents protecting this drug.
This drug has two hundred and sixty-three patent family members in forty-one countries.
The generic ingredient in ARNUITY ELLIPTA is fluticasone furoate. There are twenty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the fluticasone furoate profile page.
Summary for ARNUITY ELLIPTA
| International Patents: | 263 |
| US Patents: | 8 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 16 |
| Clinical Trials: | 2 |
| Patent Applications: | 525 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ARNUITY ELLIPTA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ARNUITY ELLIPTA |
| DailyMed Link: | ARNUITY ELLIPTA at DailyMed |
Pharmacology for ARNUITY ELLIPTA
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Synonyms for ARNUITY ELLIPTA
| (1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-DIFLUORO-14-{[(FLUOROMETHYL)SULFANYL]CARBONYL}-17-HYDROXY-2,13,15-TRIMETHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-3,6-DIEN-14-YL FURAN-2-CARBOXYLATE |
| (6|A,11|A,16|A,17|A)-6,9-Difluoro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioic Acid S-(Fluoromethyl) Ester |
| (6alpha,11alpha,14beta,16alpha,17alpha)-6,9-Difluoro-17-{[(Fluoromethyl)sulfanyl]carbonyl}-11-Hydroxy-16-Methyl-3-Oxoandrosta-1,4-Dien-17-Yl Furan-2-Carboxylate |
| 397864-44-7 |
| 6alpha,9-difluoro-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-11beta-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17alpha-yl 2-furoate |
| 779352-12-4 |
| 911210-90-7 |
| Alisade |
| Allermist |
| Avamys |
| BDBM50354851 |
| CHEBI:74899 |
| DB08906 |
| DTXSID60228586 |
| Flonase Sensimist |
| Flonase Sensimist Allergy Relief |
| Fluticasone fuorate |
| Fluticasone furancarboxylate |
| Fluticasone furoate |
| Fluticasone furoate (JAN/USAN/INN) |
| Fluticasone furoate [USAN:INN] |
| FLUTICASONEFUROATE |
| fluticasonum furoas |
| FT-0668768 |
| Furamist |
| furoate de fluticasone |
| furoato de fluticasona |
| GSK 685 698 |
| GSK 685698 |
| GW 685698 |
| GW 685698X |
| GW-685698 |
| GW-685698X |
| GW6 |
| gw685698 |
| GW685698X |
| JS86977WNV |
| PL010437 |
| SCHEMBL140504 |
| UNII-JS86977WNV |
| Veramyst |
| Veramyst (TN) |
| ZINC3992105 |
US Patents and Regulatory Information for ARNUITY ELLIPTA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-003 | May 17, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-001 | Aug 20, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-002 | Aug 20, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-003 | May 17, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-003 | May 17, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-001 | Aug 20, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-002 | Aug 20, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for ARNUITY ELLIPTA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-002 | Aug 20, 2014 | ➤ Sign Up | ➤ Sign Up |
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-001 | Aug 20, 2014 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
International Patents for ARNUITY ELLIPTA
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Canada | 2555347 | ➤ Sign Up |
| South Korea | 101496791 | ➤ Sign Up |
| Portugal | 1786498 | ➤ Sign Up |
| Japan | 2004505990 | ➤ Sign Up |
| South Korea | 100827379 | ➤ Sign Up |
| Germany | 60331891 | ➤ Sign Up |
| Japan | 5150607 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for ARNUITY ELLIPTA
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0067 | France | ➤ Sign Up | PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215 |
| C0014 | France | ➤ Sign Up | PRODUCT NAME: FLUTICASONE FLUORATE; REG. NO/DATE: EU/1/07/434/001 20080111 |
| 0343 | Netherlands | ➤ Sign Up | 300343, 20210803, EXPIRES: 20230110 |
| 269 | Luxembourg | ➤ Sign Up | PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE |
| C011/2008 | Ireland | ➤ Sign Up | SPC011/2008: 20081105, EXPIRES: 20230110 |
| 429 | Luxembourg | ➤ Sign Up | 91429, EXPIRES: 20230111 |
| 6 | Finland | ➤ Sign Up | |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
